This preview shows pages 1–2. Sign up to view the full content.
This preview has intentionally blurred sections. Sign up to view the full version.View Full Document
Unformatted text preview: Pfizer acquires Wyeth for $68bn US drugmaker Pfizer is to buy rival Wyeth in a deal worth $68bn (50bn), the two companies have announced. The merger will allow Pfizer to protect itself from a drop in revenues when its popular drug Lipitor and other products lose patent protection. It will also help Pfizer diversify its product portfolio, thanks to Wyeth's presence in biotech drugs and vaccines. The deal could wipe out nearly 20,000 jobs, adding to the wave of job cuts announced on Monday. Pfizer also said it planned to shut some manufacturing sites. Deals of this quality and this magnitude will rekindle enthusiasm and hope about equity markets Andre Bakhos, Princeton Financial Group It also reported a 90% drop in profit to $268m in the fourth quarter, because of a $2.3bn legal settlement. Pfizer that there would be a total staff reduction of 15% of the combined firms' workforce of 130,000 - implying a total job loss of 19,500....
View Full Document